The spectrum of thyroid disorders in systemic lupus erythematosus

Kumar, Kundan; Kole, Alakes Kumar; Karmakar, Partha; Ghosh, Alakendu

doi:10.1007/s00296-010-1556-5

Cited by 81 publications

(98 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kumar et al 31 found that the presence of thyroid dysfunction was greater in patients with high degrees of disease activity, as measured using SLEDAI, while other studies had contrary findings. 32,33 We did not find any association either with activity or with the cumulative harm index.…”

Section: Discussionmentioning

confidence: 85%

Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study

et al. 2017

View full text Add to dashboard Cite

BACKGROUND: Thyroid autoimmunity is more common in patients with rheumatic diseases than in healthy populations. The degree of association seems subject to influence from patients' geographical location. Here, we aimed to ascertain the prevalence of thyroid autoantibodies in a cohort of patients with systemic rheumatic disease and the degree of association between its presence and inflammatory activity. DESIGN AND SETTING: Cross-sectional observational study in a rheumatology unit. METHODS: 301 patients with systemic lupus erythematosus (SLE), 210 with rheumatoid arthritis (RA), 58 with scleroderma (SSc) and 80 with spondyloarthritis (SpA) were studied regarding thyroid function (TSH and T4), anti-thyroglobulin (TgAb) and anti-thyroperoxidase (TPOab) and compared with 141 healthy controls. Disease activity in patients with rheumatic disease was assessed through appropriate indexes. RESULTS: There were more antithyroid antibodies in SLE patients with hypothyroidism (P = 0.01; odds ratio, OR 2.7; 95% confidence interval, CI: 1.20-6.26) and in those without hypothyroidism (P = 0.06; OR 2.4; 95% CI: 1.28-4.55) than in controls. SSc patients also showed P = 0.03 both with antithyroid antibodies and hypothyroidism (OR 3.4; 95% CI: 1.06-10.80) and without hypothyroidism (OR 3.1; 95% CI: 1.11-0.13). RA and SpA patients had the same prevalence as controls (P not significant). Presence of autoantibodies with and without hypothyroidism was not associated with the activity or functional indexes evaluated. CONCLUSION: SLE and SSc were associated with higher prevalence of thyroid autoantibodies in patients with and without hypothyroidism, unlike SpA and RA. There was no link between thyroid autoantibody presence and disease activity or functional impairment.

show abstract

Section: Discussionmentioning

confidence: 85%

Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These diseases have confirmed an increased prevalence among patients with thyroid disorders [5,6,7,8,9]. Based on the immunological pathogenesis of OLP, previous research has shown the presence of serum antibodies to thyroglobulin and thyroid microsomal antibodies in OLP patients [10,11].…”

Section: Introductionmentioning

confidence: 99%

Thyroid Disease and Oral Lichen Planus as Comorbidity: A Prospective Case-Control Study

García-Pola¹,

Llorente-Pendás²,

Romero³

et al. 2016

Dermatology

View full text Add to dashboard Cite

Background: Thyroid disease has been mentioned to have a possible relation to the development of oral lichen planus (OLP). Objective: Because goiter is considered endemic in many countries, we proposed to determine whether thyroid disease constitutes a comorbidity of OLP. Methods: Two hundred and fifteen patients diagnosed as having OLP were evaluated concerning their serum thyroid-stimulating hormone and thyroxine (T₄) levels. The results were contrasted with those obtained in control series of the same number of subjects matched for age and sex. Results: Diagnosis of thyroid disease was present in 15.3% of OLP patients (33/215) and in 5.2% (12/215) of the control group. In relation to OLP patients, the odds ratio of presence of thyroid disorders was 3.06 and that of using levothyroxine medication 3.21. Conclusions: In the present study, OLP patients were associated with thyroid disease, specifically with hypothyroidism. Because most thyroid patients need T₄ treatment, our findings confirmed that OLP and thyroid disease could be comorbidities.

show abstract

Section: Figurementioning

confidence: 99%

“…8,17 Multifactorial thyroid disorders are frequent in SLE patients, in which higher prevalence of hypothyroidism as well as of thyroid autoantibodies detection is widely described. 41,42 However, we did not have cases of thyroid disorders at the onset of this study, since we did not evaluate periodically the thyroid function of these patients.This study adds evidence against an interference of steroids on sCysC levels, but further randomized studies are certainly necessary to evaluate this possible association to avoid misinterpretation of this GFR marker, in patients under treatment with glucocorticoids. …”

mentioning

confidence: 99%

Are serum cystatin C levels influenced by steroid doses in lupus nephritis patients?

Silva¹,

Solorzano²,

Nishida³

et al. 2011

J. Bras. Nefrol.

View full text Add to dashboard Cite

Os níveis séricos de cistatina C sofrem infl uência da dose de corticoide em pacientes com nefrite lúpica?Are serum cystatin C levels infl uenced by steroid doses in lupus nephritis patients? 307 Do steroid doses affect serum cystatin C levels? J Bras Nefrol 2011;33(3):306-312 IntroductIonThere are many markers and methods to estimate renal function, and the gold standard used to determine glomerular filtration rate (GFR) is the measure of the clearances of exogenous substances, such as inulin, iohexol, Cr 5 ¹-EDTA, Tc 99 -DTPA and I 125 -iothalamate. 1 On the other hand, urea and creatinine serum (sCreat) levels are endogenous markers of renal function frequently used, but they present several limitations. 1,2 The inexistence of an ideal index of renal function, which is easily applicable in daily practice, imposes the search for new substances. 3 Serum cystatin C (sCysC) has been proposed as a promising marker of the GFR and it is seen as equivalent or even superior to sCreat. [4][5][6] However, it is not clear if other factors beyond renal function have an influence on sCysC levels. Initially, it was accepted there were not in vivo factors that could have interference on its levels. 7 Nevertheless, since its clinical application was initiated, conditions that could interfere on its serum concentration beyond renal function were reported, as corticosteroid therapy, thyroid dysfunction, chronic liver disease, malignancies, organ transplantation, and many others. 1,[8][9][10][11][12][13][14][15][16][17][18][19][20] In addition, some authors consider the possibility that sCysC values could be increased in the event of male gender, increasing age, weight, and height. Moreover, its levels could be influenced by smoking, similarly to C-reactive protein, as a marker of inflammation and cardiovascular mortality. [21][22][23][24] In fact, the superiority of sCysC over sCreat in the evaluation of GFR was demonstrated in some circumstances, but it is still questionable whether nonrenal factors could interfere on its levels, as the use of glucocorticoids. [7][8][9][10][11][12][13] The aim of this study is to evaluate whether corticosteroids have an influence on sCysC levels. In order to test this hypothesis, we evaluated patients with lupus nephritis using different doses of PO and IV glucocorticoids. SubjectS and methodSForty-two patients with systemic lupus erythematosus (SLE), which diagnosis was established by the presence of at least four criteria of angiotensin receptor antagonists (ARA), 25 were enrolled, and 109 blood samples were collected. These patients were followed in the Glomerulopathy Section (Division of Nephrology) of Universidade Federal de São Paulo (UNIFESP). All of them had renal involvement during the course of SLE. Patients with a previous renal biopsy were classified according to the World Health Organization (WHO) Lupus Nephritis Classification. 26 The study was approved by the Ethics Committee, and patients were included in the study after signing their informed consent.All patients included in t...

show abstract

The spectrum of thyroid disorders in systemic lupus erythematosus

Cited by 81 publications

References 29 publications

Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study

Prevalence of thyroid autoantibodies in patients with systematic autoimmune rheumatic diseases. Cross-sectional study

Thyroid Disease and Oral Lichen Planus as Comorbidity: A Prospective Case-Control Study

Are serum cystatin C levels influenced by steroid doses in lupus nephritis patients?

Contact Info

Product

Resources

About